SKB BIO-B (06990) announced that it presented several clinical research findings at the 2025 European Society for Medical Oncology (ESMO) conference held from October 17 to 21 in Berlin, Germany. The results covered various studies, including those on the TROP2-targeting antibody-drug conjugate (ADC) sac-TMT (Jiatailai®), HER2-targeting ADC A166 (also known as Shutailei®), and data related to the Claudin18.2 (CLDN18.2) ADC SKB315.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.